Overview

A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)

Status:
Recruiting
Trial end date:
2025-05-07
Target enrollment:
Participant gender:
Summary
The main aim of this study is learn more about long-term treatment of children and teenagers with ADHD for whom earlier stimulant therapy did not work. The study has two parts (A and B). In Part A, participants will take tablets of TAK-503, atomoxetine or placebo. Participants who take placebo tablets in Part A, will take TAK-503 tablets in Part B. Participants who take TAK-503 or atomoxetine tablets in Part A, will be treated with TAK-503 in Part B.
Phase:
Phase 4
Details
Lead Sponsor:
Shire
Collaborator:
Takeda Development Center Americas, Inc.
Treatments:
Atomoxetine Hydrochloride
Guanfacine